CME in Minutes: Education in Primary Care

Follow CME in Minutes: Education in Primary Care
Share on
Copy link to clipboard

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Primary Care by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for the busy primary care providers to cover the diagnosis, treatment, follow-up, and clinical management of various disease states. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

Answers in CME


    • Apr 16, 2025 LATEST EPISODE
    • every other week NEW EPISODES
    • 15m AVG DURATION
    • 174 EPISODES


    Search for episodes from CME in Minutes: Education in Primary Care with a specific topic:

    Latest episodes from CME in Minutes: Education in Primary Care

    Aditya Bardia, MD / Sara Hurvitz, MD - Making a World of Difference for Patients With HER2-Low and -Ultralow Advanced Breast Cancer: Practical Strategies to Integrate Antibody-Drug Conjugates in Special Populations

    Play Episode Listen Later Apr 16, 2025 30:09


    Please visit answersincme.com/860/95483855-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss practical strategies for integrating antibody-drug conjugates in special populations with HER2-low advanced breast cancer and essential adverse event management approaches. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.

    Elizabeth A. Thiele, MD, PhD - Enhancing Diagnosis and Long-Term Care of Patients With Lennox-Gastaut Syndrome: A Case-Based Approach to Optimizing Treatment Strategies

    Play Episode Listen Later Apr 14, 2025 19:56


    Please visit answersincme.com/JTB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric epilepsy discusses strategies for optimizing the care of children and adults with Lennox-Gastaut syndrome (LGS). Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to accurately recognize LGS in children and adults; Evaluate the latest pharmacologic treatment strategies available for patients with LGS; and Outline approaches to optimize the long-term care of patients with LGS.

    Aditya Bardia, MD / Sara Hurvitz, MD - Realizing the Potential of Antibody-Drug Conjugates in HER2-Low and -Ultralow Advanced Breast Cancer: Evolving Strategies to Individualize Care

    Play Episode Listen Later Apr 10, 2025 26:25


    Please visit answersincme.com/860/95483855-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss antibody-drug conjugates in HER2-low advanced breast cancer, including current guideline recommendations and evolving treatment considerations to optimize individualized care. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.

    Komal Jhaveri, MD, FACP - Opportunities to Personalize Care: Making the Case for TROP2-Directed ADCs in HR+, HER2- Metastatic Breast Cancer

    Play Episode Listen Later Apr 10, 2025 19:18


    Please visit answersincme.com/BCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for the management of hormone receptor–positive, HER2-negative metastatic disease. Upon completion of this activity, participants should be better able to: Identify the available TROP2-directed ADCs for management of HR+, HER2- metastatic breast cancer (mBC); Outline the efficacy and safety of available and emerging TROP2-directed ADCs for HR+, HER2- mBC; and Apply personalization factors to help identify the optimal therapy for each individual patient with HR+, HER2- mBC.

    David E. Griffith, MD - Guiding Principles in the Management of Refractory Mycobacterium Avium Complex (MAC) Pulmonary Disease: Casing the Evidence to Inform Practical Care

    Play Episode Listen Later Apr 7, 2025 19:05


    Please visit answersincme.com/FXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary infectious disease discusses management of refractory Mycobacterium avium complex (MAC) pulmonary disease. Upon completion of this activity, participants should be better able to: Identify patients with refractory Mycobacterium avium complex (MAC) pulmonary disease in a timely manner; Review guideline-recommended therapeutic approaches to enhance the treatment plan for patients with refractory MAC pulmonary disease; and Outline clinical strategies to optimize long-term care for patients with refractory MAC pulmonary disease.

    Aditya Bardia, MD / Marilyn M. Bui, MD, PhD - Bringing HER2 Low and Ultralow to Light: How to Define and Detect HER2 Status in Advanced Breast Cancer

    Play Episode Listen Later Apr 4, 2025 21:51


    Please visit answersincme.com/860/95483855-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and pathology discuss the evolving classification of HER2 status in advanced breast cancer, including HER2 low and HER2 ultralow, and its impact on treatment decisions. Upon completion of this activity, participants should be better able to: Identify strategies to enhance the identification of HER2-low and -ultralow status in patients with advanced breast cancer; and Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer,

    Nathan Falk, MD, MBA, FAAFP - Making Sense of Type 2 Inflammation Crosstalk in Chronic Diseases: Perspectives on Improving Emergency and Primary Care Collaboration

    Play Episode Listen Later Apr 2, 2025 16:48


    Please visit answersincme.com/SFM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in family and emergency medicine discuss collaborative strategies for the optimal management of type 2 inflammatory diseases. Upon completion of this activity, participants should be better able to: Specify how type 2 inflammation contributes to the pathophysiology of chronic type 2 inflammatory diseases; Recognize the cardinal signs and symptoms of diseases presenting with type 2 inflammation; Apply treatment considerations for patients with multiple type 2 inflammatory diseases; and Outline strategies for optimizing care coordination for patients with type 2 comorbidities across providers and settings.

    Thomas Martin, MD - Focusing on the Frontline: The Impact of Anti-CD38-Based Quadruplet Regimens for Transplant-Ineligible, Newly-Diagnosed Myeloma

    Play Episode Listen Later Mar 7, 2025 15:13


    Please visit answersincme.com/BCK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloma discusses the latest data in anti-CD38 quadruplet regimens in newly diagnosed multiple myeloma. Upon completion of this activity, participants should be better able to: Identify the role of anti-CD38 monoclonal antibody (mAB)–based quadruplet regimens in the treatment landscape for newly diagnosed multiple myeloma (NDMM); Review the latest clinical data of anti-CD38 mAB-based quadruplet regimens for transplant-ineligible patients with NDMM; and Analyze evidence-based strategies for optimizing outcomes with anti-CD38 mAB-based quadruplet regimens in patients with transplant-ineligible NDMM.

    James E. Galvin, MD, MPH - Voyage Through AD: From Early Detection to Collaborative Care

    Play Episode Listen Later Feb 17, 2025 14:13


    Please visit answersincme.com/WKB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses early-stage Alzheimer's Disease (AD). Upon completion of this activity, participants should be better able to: Describe the multidisciplinary process of screening patients for early-stage AD; Describe the role primary care providers play in the multidisciplinary process of diagnosing patients with early-stage AD; and Outline strategies for counseling patients and caregivers about early intervention for early-stage AD.

    Paul Gissen, MD, PhD - A Journey Through Metachromatic Leukodystrophy: From Diagnosis to Clinical Care

    Play Episode Listen Later Feb 5, 2025 13:32


    Please visit answersincme.com/TDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in metabolic diseases discusses metachromatic leukodystrophy (MLD). Upon completion of this activity, participants should be better able to: Explain the clinical burden and unmet needs in MLD; Describe the signs and symptoms of MLD to facilitate early diagnosis and intervention; and Outline potential strategies to optimize outcomes for patients with MLD.

    Arvind Dasari, MD - Leveling Up Care in the Later-Line Treatment of Metastatic Colorectal Cancer: Bringing Quality of Life to the Forefront

    Play Episode Listen Later Jan 31, 2025 14:21


    Please visit answersincme.com/BPB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in colorectal cancer discusses the latest guidelines and evidence for later-line treatment of metastatic colorectal cancer (mCRC), as well as strategies for treatment selection and survivorship care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the later-line treatment of mCRC; Discuss the clinical impact of approved later-line treatments in patients with mCRC; and Outline personalized strategies to optimize outcomes for patients with mCRC who require later-line treatment.

    Joshua Richter, MD, FACP - Enhancing Outcomes in Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Harnessing Bispecific Antibodies in Community Care

    Play Episode Listen Later Jan 8, 2025 13:53


    Please visit answersincme.com/GPV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses bispecific antibodies in the current treatment landscape of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Review the role of bispecific antibodies in the current treatment landscape of relapsed/refractory (R/R) multiple myeloma (MM); Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated R/R MM; and Describe strategies to optimize outcomes with bispecific antibodies for the treatment of R/R MM. This activity is intended for US healthcare professionals only.

    Jai Radhakrishnan, MD, MS - IgA Nephropathy in Focus: Novel Treatment Strategies for Nephrologists and PCPs

    Play Episode Listen Later Jan 3, 2025 14:51


    Please visit answersincme.com/NRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of IgA nephropathy (IgAN) discusses novel therapeutic approaches in the management of IgAN. Upon completion of this activity, participants should be better able to: Outline the unmet needs in patients with IgAN; Discuss the clinical implications of new and emerging targeted therapies in IgAN; and Identify patient-centered strategies for long-term management of IgAN.

    Arzu Yorgancioglu, MD - A Global Approach to Asthma Management: Examining Biologics

    Play Episode Listen Later Jan 2, 2025 21:31


    Please visit answersincme.com/TSJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses systemic therapy, including biologics, for the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review recommended management strategies for moderate to severe asthma; Explain the rationale for the use of biologics in the treatment of patients with moderate to severe asthma; Identify patients eligible for systemic therapy for the treatment of moderate to severe asthma; and Outline evidence-based, long-term strategies to improve lung function in patients with moderate to severe asthma.

    Scott MacDiarmid, MD - Streamlining Patient Flow: A Clinician's Guide to Optimizing the Use of Beta-3 Adrenergic Agonists for Overactive Bladder Management

    Play Episode Listen Later Jan 2, 2025 14:10


    Please visit answersincme.com/XCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in urology discuss the latest data for treatments of overactive bladder. Upon completion of this activity, participants should be better able to: Review the current treatment landscape of OAB; Discuss the clinical significance of the latest efficacy and safety data for beta-3 adrenergic agonists for the treatment of OAB; and Outline evidence-based, patient-centered strategies to optimally use beta-3 adrenergic agonists for the treatment of patients with OAB.

    Claus Bachert, MD, PhD / Cecelia Damask, DO - Managing CRSwNP With Biologic Therapies: A Global Dialogue

    Play Episode Listen Later Dec 20, 2024 18:43


    Please visit answersincme.com/KSU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in otolaryngology discuss the role of biologic therapies in chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Recognize considerations for initiating treatment with a biologic therapy in patients with CRSwNP; Review the clinical implications of the latest efficacy and safety data for novel approved biologics in CRSwNP; and Outline strategies to optimize the use of biologics in patients with CRSwNP over the long term.

    Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers

    Play Episode Listen Later Dec 17, 2024 14:11


    Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.

    Alexander I. Spira, MD, PhD, FACP - Biomarkers at the Forefront: The Crucial Role of Testing Across Solid Tumor Types

    Play Episode Listen Later Dec 13, 2024 15:03


    Please visit answersincme.com/SWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the importance of biomarker testing in solid tumors. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes across tumor types; Identify optimal strategies for implementing biomarker testing in clinical practice; and Outline patient-centered strategies to optimize outcomes following identification of actionable biomarkers/mutations.

    David Harpole, MD / Alfredo Addeo, MD - The Possibilities of Perioperative: Assessing the Use of Perioperative Immunotherapy for Resectable NSCLC

    Play Episode Listen Later Dec 12, 2024 0:31


    Please visit answersincme.com/860/94256783-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the rationale and strategies for integrating perioperative immunotherapeutic approaches to resectable NSCLC care plans, and a patient joins the conversation to share her story. Upon completion of this activity, participants should be better able to: Explain the rationale for perioperative immunotherapeutic approaches in the treatment landscape of resectable non-small cell lung cancer (rNSCLC); and Identify when perioperative immunotherapeutic approaches should be considered for patients with rNSCLC.

    Megan Huchko, MD, MPH - Isn't HPV Vaccination Only for Pre-Teens? Answering the Why and How of Adult Vaccination

    Play Episode Listen Later Dec 6, 2024 16:53


    Please visit answersincme.com/VNG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in reproductive health discusses the rationale for human papillomavirus (HPV) vaccination in appropriate adults, its clinical impact, and strategies to incorporate HPV vaccination into prevention plans. Upon completion of this activity, participants should be better able to: Recognize the rationale for HPV vaccination in appropriate adults ages 27-45 years old; Review the clinical impact of HPV vaccination in appropriate adults ages 27-45 years old; and Outline patient-centered strategies to appropriately incorporate HPV vaccination into prevention plans for eligible adults ages 27-45 years old.

    Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Advancing Care in EGFR-Mutated NSCLC: Unveiling New Horizons With ADCs

    Play Episode Listen Later Dec 2, 2024 33:10


    Please visit answersincme.com/860/93496951-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective on the treatment journey. Upon completion of this activity, participants should be better able to: Identify when perioperative immunotherapeutic approaches should be considered for patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

    Shawn Kwatra, MD - Itching to Reduce the Burden of Prurigo Nodularis: The Latest Evidence and Strategies for Optimizing Biologic Therapy

    Play Episode Listen Later Nov 29, 2024 12:57


    Please visit answersincme.com/YZW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses biologic therapy for prurigo nodularis, and a patient presents her perspective. Upon completion of this activity, participants should be better able to: Identify the therapeutic needs of patients with PN; Review the evidence for current and emerging biologic treatments for PN; and Outline how to integrate biologic therapies into the care of patients with PN.

    Csaba P. Kovesdy, MD - Integrating Nonsteroidal MRAs in Practice: A Guideline-Driven Approach to the Management of CKD and T2D

    Play Episode Listen Later Nov 29, 2024 16:12


    Please visit answersincme.com/YTP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cardiology and nephrology discuss the latest evidence and guidance on the use of nonsteroidal mineralocorticoid receptor antagonist (MRA) for the treatment of cardio-renal-metabolic conditions. Upon completion of this activity, participants should be better able to: Identify patients with type 2 diabetes (T2D) who are at high risk for chronic kidney disease (CKD) progression and cardiovascular events; Outline the clinical implications of updated CKD guidelines regarding the use of nonsteroidal MRA therapy in patients with T2D and CKD; and Describe the latest evidence on the use of nonsteroidal MRA therapies in individuals with cardio-renal-metabolic conditions.

    Erin Barrett (Wei), MD - Focusing on the Patient to Enhance Therapeutic Care: Advancing Early Diagnosis and Management of Bullous Pemphigoid

    Play Episode Listen Later Nov 29, 2024 15:10


    Please visit answersincme.com/ZPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatologic diseases discusses the diagnosis and treatment of bullous pemphigoid. Upon completion of this activity, participants should be better able to: Review the clinical impact of bullous pemphigoid (BP) on patients; Outline diagnostic approaches to enhance the timely identification of patients with BP; and Identify clinical advances that may evolve the therapeutic paradigm for patients with BP.

    René S. Kahn, MD, PhD - Elevating the Patient Voice in Bipolar I Disorder Management: A Collaborative Approach to Shared Decision-Making

    Play Episode Listen Later Nov 26, 2024 16:08


    Please visit answersincme.com/KWX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in bipolar disorder and a patient advocate discuss patient-centered care for people with bipolar I. Upon completion of this activity, participants should be better able to: Identify patient-centered strategies to optimize the timely diagnosis of bipolar I disorder (BD-I); Review goal-oriented therapeutic approaches that address the personalized needs of patients with BD-I; and Outline strategies to ensure the delivery of patient-centric care that incorporates patients' wishes, values, priorities, and goals.

    David Harpole, MD / Neel Chudgar, MD - The Practicalities of Perioperative Immunotherapy for Resectable NSCLC

    Play Episode Listen Later Nov 26, 2024 23:57


    Please visit answersincme.com/860/94256783-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective on the treatment journey. Upon completion of this activity, participants should be better able to: Identify when perioperative immunotherapeutic approaches should be considered for patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

    David S. Boyer, MD / Irving Posalski, MD - PCP-Specialists Share a Lens to Magnify Outcomes With VEGF-Targeting Agents for DME

    Play Episode Listen Later Nov 26, 2024 15:49


    Please visit answersincme.com/GCB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of diabetic macular edema (DME) discuss the primary care physician (PCP) and ophthalmologist's partnership in the care for patients with DME and optimizing treatment with VEGF-targeting agents. Upon completion of this activity, participants should be better able to: Explain how extending treatment intervals for DME can improve patient satisfaction and treatment persistence with intravitreal anti-VEGF therapy; Discuss the clinical benefits of longer-acting intravitreal anti-VEGF agents in the treatment of DME; Describe multidisciplinary care plans that improve the long-term treatment outcomes of patients with patients with DME; and Outline strategies for optimizing DME outcomes in the primary care setting. This activity is intended for US healthcare professionals only.

    David Harpole, MD / Nicolas Girard, MD, PhD - Trials and Tribulations: Examining the Data for Perioperative Immunotherapeutic Approaches in Resectable NSCLC

    Play Episode Listen Later Nov 20, 2024 31:02


    Please visit answersincme.com/860/94256783-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the clinical significance of the latest efficacy and safety data for perioperative immunotherapeutic regimens for resectable NSCLC. Upon completion of this activity, participants should be better able to: Review the significance of the latest clinical data of perioperative immunotherapeutic approaches in patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

    Jia Ruan, MD, PhD - Clinical Case Challenges in Frontline PTCL: Navigating the Landscape of CD30-Positive PTCL Treatment

    Play Episode Listen Later Nov 15, 2024 19:09


    Please visit answersincme.com/BHU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lymphoma discusses the treatment landscape for CD30-positive peripheral T-cell lymphoma (PTCL). Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations for frontline treatment of PTCL; Describe the clinical evidence informing the use of CD30-directed therapy in frontline treatment of PTCL; and Outline considerations to optimize outcomes with CD30-directed therapy for frontline treatment of patients with PTCL.

    Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Leveraging Precise Targets to Elevate Outcomes: NSCLC Treatment Strategies for HER2-Directed ADCs

    Play Episode Listen Later Nov 15, 2024 26:31


    Please visit answersincme.com/93496951-replay2860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the clinical implications of the latest data for HER2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC; and Describe practical, data-driven approaches to effectively integrate current and emerging ADCs into the management of advanced NSCLC.

    Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice

    Play Episode Listen Later Nov 6, 2024 15:35


    Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.

    Christoph U. Correll, MD - Transforming the Treatment of Schizophrenia: Moving Beyond Anti-Dopaminergic Antipsychotics to Muscarinic Receptor Agonists

    Play Episode Listen Later Nov 6, 2024 15:23


    Please visit answersincme.com/DKN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses antipsychotics in schizophrenia. Upon completion of this activity, participants should be better able to: Explain the rationale for targeting muscarinic receptors in the treatment of schizophrenia; Describe the clinical implications of evidence on muscarinic receptor agonists in the treatment of schizophrenia; and Outline strategies for optimally incorporating muscarinic receptor agonists into the treatment of patients with schizophrenia.

    Evan S. Dellon, MD, MPH - In Case of Emergency: Ensuring Timely Recognition and Intervention in Patients With Eosinophilic Esophagitis

    Play Episode Listen Later Nov 6, 2024 13:02


    Please visit answersincme.com/WSK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Evan S. Dellon, MD, MPH, an expert in esophageal disease, discusses best practices to facilitate timely diagnosis of eosinophilic esophagitis (EoE) through symptom recognition and referral at the emergency department. Upon completion of this activity, participants should be better able to: Recognize the consequences of untreated eosinophilic esophagitis (EoE), including the burden of food impaction; Identify best practices to facilitate the timely diagnosis and management of EoE through symptom recognition and referral; and Review the available therapeutic modalities for EoE that support the need for timely referral. This activity is intended for US healthcare professionals only.

    Jacob Sands, MD / Raffaele Califano, MD - Novel ADC Targets in Advanced NSCLC: Examining Emerging Strategies for TROP2-Directed ADCs

    Play Episode Listen Later Oct 30, 2024 27:05


    Please visit answersincme.com/93496951-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the significance of the latest data for TROP2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; and Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC.

    Juliana M. Kling, MD, MPH - Turning Down the Heat: Exploring Newly Approved and Emerging Nonhormonal Therapies for Menopause-Associated VMS

    Play Episode Listen Later Oct 7, 2024 12:59


    Please visit answersincme.com/VAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women's health and menopause discusses novel, nonhormonal strategies to treat vasomotor symptoms (VMS) associated with menopause. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel nonhormonal therapies in the treatment of VMS associated with menopause; Review the clinical profiles of approved and emerging novel nonhormonal treatments of VMS associated with menopause; Outline patient-centered, evidence-based strategies to optimize the treatment of common menopausal symptoms

    Christoph U. Correll, MD - Pathways to Hope: Emerging Therapies in Alzheimer's Disease Psychosis

    Play Episode Listen Later Sep 27, 2024 16:01


    Please visit answersincme.com/UYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses novel treatment options being investigated for patients with Alzheimer's disease psychosis (ADP). Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in managing patients with Alzheimer's disease psychosis (ADP); Review the rationale for using therapies with novel mechanisms for the treatment of patients with ADP; Describe the implications of the latest data on novel therapies for managing patients with ADP.

    Stephanie A. Christenson, MD, MAS - ​Targeting Eosinophils for Fewer Exacerbations:​ The Future of Biologic Treatments in COPD Management

    Play Episode Listen Later Sep 20, 2024 14:21


    Please visit answersincme.com/PES860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary disease discusses the implications of the latest evidence on biologic therapies targeting type 2 inflammation for the treatment of chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify the rationale for investigating biologics targeting type 2 inflammation for the treatment of patients with chronic obstructive pulmonary disease (COPD); Review the clinical impact of emerging biologics in the treatment of eosinophilic COPD in patients at high risk of exacerbations; Outline strategies to implement biologics targeting type 2 eosinophilic inflammation into clinical practice, as they become available. This activity is intended for US healthcare professionals only.

    Joyce O'Shaughnessy, MD - Harnessing Immunotherapy for Early Breast Cancer Management: Neoadjuvant Updates in HR-Positive, HER2-Negative Disease

    Play Episode Listen Later Sep 20, 2024 14:37


    Please visit answersincme.com/ZFZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of immunotherapy in neoadjuvant treatment of early breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for adding immunotherapy to chemotherapy in the neoadjuvant treatment of early HR-positive, HER2-negative breast cancer; Identify the clinical implications of the latest data for neoadjuvant treatment with immunotherapy plus chemotherapy regimens in early HR-positive, HER2-negative breast cancer; Describe the role that neoadjuvant, immunotherapy-containing regimens might play in the future management of patients with early HR-positive, HER2-negative breast cancer, including high risk patients

    Ahmad Tarhini, MD, PhD - Adjuvant Approaches in High-Risk, Resectable Melanoma: A Practical Guide to Improving Outcomes With Immunotherapy-Based Regimens

    Play Episode Listen Later Sep 19, 2024 14:24


    Please visit answersincme.com/RKX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer discusses strategies for adjuvant immunotherapy in resectable melanoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended role of adjuvant immunotherapy for the treatment of resectable melanoma; Describe the key adverse events associated with adjuvant immunotherapy for the treatment of resectable melanoma; Outline evidence-based, patient centric strategies to optimize the benefit-to-risk impact of adjuvant immunotherapy in resectable melanoma care

    David M. Miller, MD, PhD / Todd Schlesinger, MD - A Clinician's Roadmap to Improving Outcomes in Advanced Basal Cell Carcinoma: Guiding Principles for the Use of Immunotherapies

    Play Episode Listen Later Sep 13, 2024 16:17


    Please visit answersincme.com/GEU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the management of advanced basal cell carcinoma (BCC) with immunotherapies, based on the guidelines and clinical evidence. Upon completion of this activity, participants should be better able to: Review the guideline recommendations for the treatment of advanced BCC; Identify the clinical implications of the available evidence evaluating immunotherapy options for patients with advanced BCC; and Outline real-world considerations for the integration of immunotherapy into practice for the management of advanced BCC. This activity is intended for US healthcare professionals only.

    Vasu Divi, MD, MS - Neoadjuvant Immunotherapy for CSCC: Practical Considerations for Resectability, Patient Selection, and Treatment Optimization

    Play Episode Listen Later Sep 9, 2024 12:35


    Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe clinical factors that should be considered when evaluating whether a patient with CSCC is a candidate for neoadjuvant immunotherapy; Review the clinical profiles of approved and emerging neoadjuvant immunotherapies for patients with resectable CSCC; and Outline practical considerations to optimize treatment outcomes for patients with resectable CSCC. This activity is intended for US healthcare professionals only.

    Leonard B. Bacharier, MD - Highlighting the Use of Biologics in Pediatric Patients: Case Scenarios to Elevate Asthma Treatment

    Play Episode Listen Later Sep 9, 2024 16:44


    Please visit answersincme.com/YCT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric asthma discusses early intervention with biologic therapy for children with moderate to severe asthma. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with asthma who may benefit from treatment intensification with biologic therapy; Outline the clinical impact of add-on biologics approved for the treatment of pediatric patients with moderate to severe asthma; and Identify patient-centered strategies to optimize outcomes for pediatric patients with inadequately controlled moderate to severe asthma. This activity is intended for US healthcare professionals only.

    Mark Awad, MD, PhD - Advancing the Therapeutic Landscape of SCLC with B7-H3–Targeted Antibody-Drug Conjugates: Insights and Future Directions

    Play Episode Listen Later Sep 9, 2024 12:49


    Please visit answersincme.com/BXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses B7-H3–directed antibody-drug conjugates as a treatment strategy for small-cell lung cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for developing antibody-drug conjugates (ADCs) targeting B7-H3 as treatment for extensive-stage small-cell lung cancer (ES-SCLC); Review the preliminary efficacy and safety data for emerging B7-H3–directed ADCs for the treatment of pretreated ES-SCLC; and Describe key clinical considerations for the future use of B7-H3–directed ADCs in ES-SCLC.

    Vibeke Strand, MD / April W. Armstrong, MD, MPH - A New Take on TYK2 Inhibitors: Bridging Gaps in Psoriatic Arthritis Management With Novel Targeted Therapies

    Play Episode Listen Later Sep 4, 2024 19:56


    Please visit answersincme.com/UNV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology, immunology, and rheumatology discuss the management of psoriatic arthritis with novel targeted therapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel TYK2 inhibitors in the treatment of psoriatic arthritis; Describe the latest clinical data informing the role of TYK2 inhibitors in the treatment of psoriatic arthritis; and Outline future management considerations for novel TYK2 inhibitors in the treatment of psoriatic arthritis.

    Cecelia Damask, DO - Evidence-Based Approaches to Sequencing and Switching Biologic Therapies in Patients With CRSwNP and Comorbidities

    Play Episode Listen Later Aug 16, 2024 18:09


    Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.

    Aditya Bardia, MD - From Theory to Practice: Enhancing Antibody-Drug Conjugate Integration in HER2-Low Advanced Breast Cancer

    Play Episode Listen Later Aug 9, 2024 18:36


    Please visit answersincme.com/TBW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer offers guidance for determining HER2 status in patients with advanced breast cancer, and shares insights on clinical data and strategies to optimize the use of antibody-drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Review the guideline recommendations to optimize the identification of patients with HER2-low advanced breast cancer; Outline the clinical implications of the most recent data evaluating the use of available ADCs in the treatment of HER2-low advanced breast cancer; and Identify practical strategies to optimize outcomes with ADC treatment for real-world patient populations with HER2-low advanced breast cancer.

    Rami Komrokji, MD - Navigating the First-Line Treatment Landscape of Anemia in Lower-Risk MDS: Translating the Latest Data to Practice

    Play Episode Listen Later Aug 5, 2024 13:13


    Please visit answersincme.com/VWG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses patient selection and treatment for myelodysplastic syndromes. Upon completion of this activity, participants should be better able to: Identify practical strategies for risk stratification and mutation analysis of patients with myelodysplastic syndromes (MDS) to enable risk-adapted therapy; Review the clinical profiles of conventional and newly approved therapies to treat anemia in patients with lower-risk MDS; and Describe the impact of recent data on treatment practices for the management of anemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk MDS.

    Stephanie E. Combs, MD / Heather Wakelee, MD - A Growing Need for Targeted Approaches in Unresectable Stage III NSCLC: A Clinical Evaluation of Evolving Data in EGFR Mutation–Positive Disease

    Play Episode Listen Later Aug 5, 2024 15:59


    Please visit answersincme.com/CFN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in oncology discuss current and emerging treatments for unresectable stage I to III EGFR mutation–positive non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Review best practices for integrating biomarker testing into practice for stage I to III NSCLC; Describe the clinical profiles of current and emerging therapeutic approaches for the management of stage I to III NSCLC; and Outline multidisciplinary strategies to optimize the integration of a targeted approach into clinical practice for patients with stage I to III NSCLC.

    Eileen Wang, MD, MPH - Breathing Life Into Type 2 Asthma: Advancing Clinical Remission With Biologics

    Play Episode Listen Later Aug 5, 2024 13:51


    Please visit answersincme.com/WMY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy and immunology discusses incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. Upon completion of this activity, participants should be better able to: Define “clinical remission” of asthma; and Review the impact of approved biologics for the treatment of patients with T2 asthma on clinical remission; Outline strategies for incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. This activity is intended for US healthcare professionals only.

    Luis Paz-Ares, MD, PhD - Exploring the Potential of TROP2 ADCs for Advanced/Metastatic NSCLC: Implications for Practice

    Play Episode Listen Later Jul 12, 2024 12:10


    Please visit answersincme.com/YSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the practical implications of emerging TROP2 antibody–drug conjugates (ADCs) for the management of advanced or metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Discuss the rationale for targeting TROP2 in patients with advanced or metastatic NSCLC; Review the clinical profiles of emerging ADCs targeting TROP2 in patients with advanced or metastatic NSCLC; and Identify clinical strategies to optimize management of patients with advanced NSCLC treated with TROP2-directed ADCs, as they become available.

    Chris Verslype, MD, PhD - Optimizing TKI Therapy for Individualized Advanced HCC Treatment: Taking a Real-World Perspective

    Play Episode Listen Later Jul 12, 2024 24:37


    Please visit answersincme.com/UYD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology and digestive oncology discusses guidance for use of TKI therapy in advanced hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Describe evidence for the optimal use of tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC); Identify patient- and disease-based factors which guide the use of TKI therapy for the treatment of advanced HCC; and Outline strategies to develop personalized treatment plans to maximize clinical outcomes using TKI therapies in the treatment of advanced HCC.

    Claim CME in Minutes: Education in Primary Care

    In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

    Claim Cancel